Zealand Pharma A/S
The answer first
Does Zealand Pharma beat the market?
No, Zealand Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 73% of Nordic stocks
- Quality95
- Value85
- Trend7
No. 33 of 195 in healthcare
Max for seven days
Follow Zealand Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Zealand Pharma
Your first answer is free, no account needed.
Do you own Zealand Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Zealand Pharma and a few more. Free, no card.
Super Stock+45.3%In short
- Zealand Pharma has fallen 61.6% over the past year, including dividends.
- Overall, Zealand Pharma ranks better than 73% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 78.0%. The price is 78.0% below its peak now.
What do analysts think of Zealand Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 73% of Nordic stocks.
No. 33 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 20 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.03
- Asset turnoverSales divided by everything the company owns0.31
- Return on equityProfit divided by equity+26.9%
- Cash conversionOperating cash flow divided by profit−0.13
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 11 of 197 in healthcareTypical in healthcare: 19Typical in the Nordics: 50
- P/BPrice divided by equity0.8
- P/SPrice divided by sales2.4
- P/EPrice divided by earnings3.1
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 167 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−35.8%
- 6 months−35.0%
- 9 months−45.2%
- 12 months−61.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Zealand Pharma
20 funds we follow own Zealand Pharma. The share is how much of the fund the stock makes up.
- Norway1
- Sweden12
- Denmark7
- 2 ETFs
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo1.5%
- Xact KapitalforvaltningDenmark · XACT · ETF1.0%
- Nordnet Indeksfond Danmark ASweden · Nordnet1.0%
- BIX Danske Aktier Indeks ADenmark · BIX0.6%
- BIX Danske Aktier Indeks Akk ADenmark · BIX0.6%
- Danske Invest Danmark IndeksDenmark · Danske Invest0.6%
- Sparindex INDEX OMX C25 KLDenmark · Sparindex0.5%
- Sparinvest INDEX OMX C25 KLDenmark · Sparinvest0.5%
Show all 20
- Sydinv Indeks Danmark A DKKDenmark · Sydinvest0.3%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.3%
- Skandia VärldenSweden · Skandia0.3%
- Handelsbanken Nordenfond (A1 NOK)Sweden · Handelsbanken0.2%
- Xact NordenSweden · XACT · ETF0.2%
- KLP AksjeNorden IndeksNorway · KLP0.1%
- Handelsbanken Gl Småbolag I Crit A9 EURSweden · Handelsbanken0.0%
- Handelsbanken Gl Småbolag Ind Cri A1 NOKSweden · Handelsbanken0.0%
- Meriti Ekorren Global ASweden · Meriti0.0%
- SEB Dynamisk AktiefondSweden · SEB0.0%
- SEB Active 55 ASweden · SEB0.0%
- SEB Active 80 ASweden · SEB0.0%
From the funds' latest known holdings.
About Zealand Pharma
Zealand Pharma A/S is a company in healthcare, listed on Nasdaq Copenhagen. By market value, Zealand Pharma is number 10 of 20 companies in healthcare on Nasdaq Copenhagen. Zealand Pharma has not paid a dividend in the past twelve months. Of the three measures in the ranking, Zealand Pharma is strongest on quality, better than 95% of Nordic stocks. The next report from Zealand Pharma is expected on 25 February 2027. The share trades in DKK. It has around 600 employees.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism.


See the full analysis of Zealand Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card